Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men

被引:64
|
作者
Florvall, Gosta
Basu, Samar
Larsson, Anders [1 ]
机构
[1] Univ Uppsala Hosp, Dept Med Sci, Sect Clin Chem, S-75185 Uppsala, Sweden
[2] Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci, S-75185 Uppsala, Sweden
关键词
D O I
10.1093/gerona/61.12.1262
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The aim of this study was to compare apolipoprotein A1 (ApoA1) and B (ApoB) with high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) as markers for cardiovascular mortality and morbidity in elderly men. We analyzed serum ApoA1, ApoB, total cholesterol, HDL-C, and LDL-C in a group of 77-year-old men (n = 785). The results were correlated with data from the Swedish cause of death registry. Receiver-operating characteristic curves showed that, of the studied serum markers, ApoA I was the best predictor for ischemic heart disease mortality (area under the curve = 0.724, 95% confidence interval, 0.691-0.755). There were also significant correlations between the apolipoproteins and other known risk markers for cardiovascular disease such as triglycerides, high-sensitivity C-reactive protein (hsCRP), and cystatin C. Serum ApoA1 is a better risk marker than are ApoB, ApoB/ApoA1 ratio, HDL-C, and LDL-C for cardiovascular disease and mortality in elderly men.
引用
收藏
页码:1262 / 1266
页数:5
相关论文
共 25 条
  • [21] Joint effect of visit-to-visit variability in LDL-cholesterol, HDL-cholesterol and HbA1c on cardiovascular and total mortality in patients with diabetes
    He, Panpan
    Gan, Xiaoqin
    Wu, Qimeng
    Ye, Ziliang
    Yang, Sisi
    Zhang, Yanjun
    Li, Huan
    Zhou, Chun
    Zhang, Yuanyuan
    Liu, Mengyi
    Qin, Xianhui
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [22] FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
    Bikov, Andras
    Lange, Peter
    Anderson, Julie A.
    Brook, Robert D.
    Calverley, Peter M. A.
    Celli, Bartolome R.
    Cowans, Nicholas J.
    Crim, Courtney
    Dixon, Ian J.
    Martinez, Fernando J.
    Newby, David E.
    Yates, Julie C.
    Vestbo, Jorgen
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 1135 - 1142
  • [23] Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol
    Bergheanu, S. C.
    Van Tol, A.
    Dallinga-Thie, G. M.
    Liem, A.
    Dunselman, P. H. J.
    Van Der Bom, J. G.
    Jukema, J. W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (09) : 2235 - 2240
  • [24] TARGETING ABSOLUTE LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AS A BETTER APPROACH THAN STARTING STATINS BASED ON INITIAL BASELINE LDL FOR PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND MORTALITY: A META-REGRESSION
    Singh, Bishnu Mohan
    Singh, Nisha
    Raut, Anuradha
    Singh, Puja
    Gonzalez, Maday
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1845 - 1845
  • [25] New Challenges for HDL-Modifying Therapies as a Strategy to Lower Cardiovascular Disease Events in Statin-Treated PatientsEditorial to: “Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High Density Lipoprotein” by E.J. Niesor et al.
    Robert S. Rosenson
    H. Bryan Brewer
    Cardiovascular Drugs and Therapy, 2015, 29 (1) : 1 - 3